Between 2019 and the middle of 2026, the share of American children aged 8 to 11 with obesity who were prescribed a GLP-1 drug rose 310-fold, from 0.03 percent to 9.3 percent. Put plainly: at the start of that window almost none of these grade-schoolers were on the drugs, and by this year close to one in ten were. The jump is real and steep. It is also still, in absolute terms, a minority of the children who qualify.
Those two facts are the whole story, and they pull in opposite directions. The numbers come from a study published September 4 in Pediatrics ↗, the journal of the American Academy of Pediatrics, which tracked prescribing in children aged 8 to 11 who had obesity but not diabetes. The drugs involved were the familiar three: liraglutide ↗, semaglutide ↗, and tirzepatide ↗, all of which quiet appetite by acting on the GLP-1 receptor ↗.
Who is actually getting them
The reassuring part is who the prescriptions went to. This was not a wave of lightly-affected kids handed a shortcut. Among the children who received a drug, 93.7 percent had class II or class III obesity, the two most severe categories, meaning weights far enough above the healthy range to carry real medical risk. About 65.2 percent already had at least one weight-related complication, such as high blood pressure or fatty liver, and roughly a quarter had prediabetes, blood sugar creeping toward the diabetic range. On paper, this is the group that pediatric obesity medicine says should be treated most aggressively. The prescriptions are concentrating where the disease is worst, not scattering across the merely chubby.
The unsettling part is the age. Eight to eleven is younger than where most of the evidence lives. The large trials that built the case for these drugs in young people ran in adolescents, and the study testing semaglutide in children as young as six, Novo Nordisk's STEP Young trial, only reported its main result this same week. So the prescribing curve in grade-schoolers climbed for years while the trial meant to justify it was still running. Practice ran ahead of the proof.
Why a prescribing count is not an outcomes study
It is worth being precise about what this study can and cannot say. It counts prescriptions, not results. It does not tell us whether these particular children lost weight, kept it off, avoided diabetes, or grew normally on the drugs, and it does not follow them long enough to catch anything that shows up years later. A database of prescriptions is a record of decisions doctors and families made, not a verdict on whether those decisions worked. The 9.3 percent figure is a snapshot of behavior, and behavior can outrun evidence in either direction.
That is the tension a parent or pediatrician is left holding. Severe obesity in a nine-year-old is not a cosmetic problem. It shortens the runway to type 2 diabetes and heart disease, and the older cautious answer, diet and exercise alone, has a long record of not working at scale. Against that, these drugs are new in this age group, taken by mouth or needle for what may be years, and studied mostly in people a decade older or more. Earlier reporting on adolescents offered one piece of comfort: a small chart review found that starting a GLP-1 drug did not worsen teenagers' depression or suicidal thinking ↗, and scores actually fell. That is encouraging and thin, one clinic and a few dozen patients.
The honest read is that the prescribing has moved faster than the long-term evidence in the youngest patients, and it is pointed, for now, at the children who are sickest. Whether that is good medicine or getting ahead of the data is the question the next few years of follow-up, not this prescribing count, will answer.